Reference  is made  to the  stock exchange  announcement by  Hofseth Biocare ASA
("HBC"  or the "Company")  on 27 October 2025 regarding  completion of a private
placement (the "Private Placement") of new shares in the Company.

In  the Private Placement, Hofseth International AS was allocated 28,666,666 new
shares at the subscription price of NOK 1.80.

Please refer to the attached notification form for further information.

This  information  is  subject  to  the  disclosure requirements pursuant to the
Market Abuse Regulation article 19.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)
